{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:35:28Z","timestamp":1789850128485,"version":"4.0.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS","doi-asserted-by":"publisher","award":["JP12345678"],"award-info":[{"award-number":["JP12345678"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tolvaptan, a vasopressin V2 receptor antagonist, is used for treating autosomal dominant polycystic kidney disease (ADPKD). We focused on changes in urinary osmolality (U-Osm) after tolvaptan initiation to determine whether they were associated with the therapeutic response to tolvaptan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a single-centre, prospective, observational cohort study. Seventy-two patients with ADPKD who received tolvaptan were recruited. We analysed the relationship between changes in U-Osm and annual estimated glomerular filtration rate (eGFR) in terms of renal prognostic value using univariable and multivariable linear regression analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean value of U-Osm immediately before tolvaptan initiation was 351.8\u00a0\u00b1\u00a0142.2 mOsm\/kg H2O, which decreased to 97.6\u00a0\u00b1\u00a023.8 mOsm\/kg H2O in the evening. The decrease in U-Osm was maintained in the outpatient clinic 1 month later. However, the 1-month values of U-Osm showed higher variability (160.2\u00a0\u00b1\u00a083.8 mOsm\/kg H2O) than did those in the first evening of tolvaptan administration. Multivariate analysis revealed that the baseline eGFR, baseline urinary protein and U-Osm change in the evening of the day of admission (initial U-Osm drop) were significantly correlated with the subsequent annual change in eGFR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>U-Osm can be measured easily and rapidly, and U-Osm change within a short time after tolvaptan initiation may be a useful index for the renal prognosis in actual clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfad232","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T01:42:00Z","timestamp":1699407720000},"page":"1008-1015","source":"Crossref","is-referenced-by-count":3,"title":["Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with ADPKD"],"prefix":"10.1093","volume":"39","author":[{"given":"Taro","family":"Akihisa","sequence":"first","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9543-7608","authenticated-orcid":false,"given":"Hiroshi","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Makabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Manabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ushio","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiji","family":"Yajima","sequence":"additional","affiliation":[{"name":"Department of Blood Purification, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Hanafusa","sequence":"additional","affiliation":[{"name":"Department of Blood Purification, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Blood Purification, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"2024053023530450900_bib1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneph.2016.135","article-title":"The importance of total kidney volume in evaluating progression of polycystic kidney disease","volume":"12","author":"Grantham","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2024053023530450900_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ekir.2021.12.012","article-title":"Germline mutations for kidney volume in ADPKD","volume":"7","author":"Kataoka","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2024053023530450900_bib3","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"key":"2024053023530450900_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/jcm9010146","article-title":"Prediction of renal prognosis in patients with autosomal dominant polycystic kidney disease using PKD1\/PKD2 mutations","volume":"9","author":"Kataoka","year":"2020","journal-title":"J Clin Med"},{"key":"2024053023530450900_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrneph.2012.139","article-title":"Polycystic kidney disease: an early urea-selective urine-concentrating defect in ADPKD","volume":"8","author":"Bankir","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2024053023530450900_bib6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ki.2012.225","article-title":"Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation","volume":"82","author":"Ho","year":"2012","journal-title":"Kidney Int"},{"key":"2024053023530450900_bib7","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s10157-021-02097-6","article-title":"A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020","volume":"25","author":"Nishio","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2024053023530450900_bib8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10157-015-1219-7","article-title":"Evidence-based clinical practice guidelines for polycystic kidney disease 2014","volume":"20","author":"Horie","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"2024053023530450900_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10157-023-02372-8","article-title":"Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease","volume":"27","author":"Kataoka","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"2024053023530450900_bib10","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.ekir.2021.05.037","article-title":"Tolvaptan in ADPKD patients with very low kidney function","volume":"6","author":"Torres","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024053023530450900_bib11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.34067\/KID.0007342020","article-title":"Dose-dependent effect of tolvaptan on renal prognosis in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Akihisa","year":"2021","journal-title":"Kidney360"},{"key":"2024053023530450900_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"2024053023530450900_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/j.ajkd.2015.03.004","article-title":"Acute response to tolvaptan in ADPKD: a window to predict long-term efficacy?","volume":"65","author":"Reddy","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2024053023530450900_bib14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s10157-022-02192-2","article-title":"Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease","volume":"26","author":"Akihisa","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"2024053023530450900_bib15","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024053023530450900_bib16","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.ekir.2021.06.033","article-title":"Urinary aquaporin 2 as a potential indicator predicting tolvaptan response in patients with ADPKD","volume":"6","author":"Makabe","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024053023530450900_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10157-017-1475-9","article-title":"Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study","volume":"22","author":"Minami","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2024053023530450900_bib18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet North Am Ed"},{"key":"2024053023530450900_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2012.07.007","article-title":"GFR estimation using standardized serum cystatin C in Japan","volume":"61","author":"Horio","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2024053023530450900_bib20","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"2024053023530450900_bib21","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2024053023530450900_bib22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2024053023530450900_bib23","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2024053023530450900_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0962280214548822","article-title":"Joint modelling compared with two stage methods for analysing longitudinal data and prospective outcomes: a simulation study of childhood growth and BP","volume":"26","author":"Sayers","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"2024053023530450900_bib25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/j.ajkd.2020.01.019","article-title":"Metabolomic markers of kidney function decline in patients with diabetes: evidence from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"76","author":"Kwan","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2024053023530450900_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2020.07.011","article-title":"Novel risk factors for progression of diabetic and nondiabetic CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"77","author":"Anderson","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2024053023530450900_bib27","doi-asserted-by":"crossref","first-page":"e002290","DOI":"10.1136\/bmjopen-2012-002290","article-title":"Predictors of non-response in a UK-wide cohort study of children's accelerometer-determined physical activity using postal methods","volume":"3","author":"Rich","year":"2013","journal-title":"BMJ Open"},{"key":"2024053023530450900_bib28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jclinepi.2014.12.014","article-title":"The number of subjects per variable required in linear regression analyses","volume":"68","author":"Austin","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"2024053023530450900_bib29","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: new guidance for publication in BJP","volume":"172","author":"Curtis","year":"2015","journal-title":"Br J Pharmacol"},{"key":"2024053023530450900_bib30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease","volume":"35","author":"Gabow","year":"1989","journal-title":"Kidney Int"},{"key":"2024053023530450900_bib31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024053023530450900_bib32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2215\/CJN.10470620","article-title":"Use of the urine-to-plasma urea ratio to predict ADPKD progression","volume":"16","author":"Heida","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024053023530450900_bib33","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1073\/pnas.0401704101","article-title":"Urinary concentrating defect in mice with selective deletion of phloretin-sensitive urea transporters in the renal collecting duct","volume":"101","author":"Fenton","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024053023530450900_bib34","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2005.03.004","article-title":"Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure","volume":"95","author":"Goldsmith","year":"2005","journal-title":"Am J Cardiol"},{"key":"2024053023530450900_bib35","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad232\/53692519\/gfad232.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/6\/1008\/58008298\/gfad232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/6\/1008\/58008298\/gfad232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T01:07:44Z","timestamp":1717117664000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/6\/1008\/7342462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11,3]]},"published-print":{"date-parts":[[2024,5,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad232","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2023,11,3]]}}}